Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Exact Sciences Corporation    EXAS

EXACT SCIENCES CORPORATION

(EXAS)
  Report
Delayed Quote. Delayed Nasdaq - 11/27 01:00:00 pm
118.19 USD   +2.00%
11/27EXACT SCIENCES CORP : Other Events (form 8-K)
AQ
11/10EXACT SCIENCES : Code of Business Conduct and Ethics
PU
11/10EXACT SCIENCES : Policy Governing Director Nominations
PU
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

EXACT SCIENCES CORP : Change in Directors or Principal Officers (form 8-K)

04/24/2020 | 08:14am EST

Item 5.02 Departure of Directors or Principal Officers; Election of Directors;

           Appointment of Principal Officers.



On April 22, 2020, the Board of Directors of Exact Sciences Corporation (the "Company") appointed Freda Lewis-Hall, M.D., DFAPA to serve as a Class II director until the 2020 Annual Meeting of Stockholders.

Dr. Lewis-Hall served as Chief Patient Officer and Executive Vice President of Pfizer Inc. (NYSE: PFE) from January 2019 to December 2019. She acted as a Senior Medical Advisor to the CEO until her retirement in March 2020. From 2009 to December 2019, Dr. Lewis-Hall served as Pfizer's Chief Medical Officer and Executive Vice President. Prior to joining Pfizer in 2009, Dr. Lewis-Hall held various senior leadership positions including Chief Medical Officer and Executive Vice President, Medicines Development at Vertex Pharmaceuticals, Inc., a biopharmaceutical company, from 2008 to 2009, and Senior Vice President, U.S. Pharmaceuticals, Medical Affairs for Bristol-Myers Squibb Co. from 2003 to 2008.

Dr. Lewis-Hall serves on the board of directors of SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) and 1Life Healthcare, Inc. (NASDAQ: ONEM). From December 2014 to May 2017, she served on the board of directors of Tenet Healthcare Corporation (NYSE: THC). Dr. Lewis-Hall currently serves on the board of fellows of The Harvard School and the board of advisors of the Dell Medical School. She also serves as a member of the board of governors for the Patient-Centered Outcomes Research Institute. Dr. Lewis-Hall earned a B.A. in Natural Sciences from Johns Hopkins University and an M.D. from Howard University College of Medicine.

Dr. Lewis-Hall will receive compensation for her service as a director in accordance with the Company's Non-Employee Director Compensation Policy filed herewith as Exhibit 10.1 and incorporated herein by reference (the "Director Compensation Policy"). Pursuant to the Non-Employee Director Compensation Policy, in connection with her initial appointment to the Board of Directors, Dr. Lewis-Hall received a stock award valued at $375,000.

9.01. Financial Statements and Exhibits.




Exhibits


The following exhibit is filed herewith:



Exhibit No.                             Exhibit Description

   10.1           Non-Employee Director Compensation Policy dated April 22, 2020.

    104         Cover Page Interactive Data File (embedded within the Inline XBRL
                document)




                                       2

© Edgar Online, source Glimpses

All news about EXACT SCIENCES CORPORATION
11/27EXACT SCIENCES CORP : Other Events (form 8-K)
AQ
11/10EXACT SCIENCES : Code of Business Conduct and Ethics
PU
11/10EXACT SCIENCES : Policy Governing Director Nominations
PU
10/27EXACT SCIENCES : to buy cancer-screening firm Thrive Earlier Detection in $2.15 ..
RE
10/27EXACT SCIENCES : Infographic
PU
10/27EXACT SCIENCES : 3Q Earnings Snapshot
AQ
10/27EXACT SCIENCES : Management's Discussion and Analysis of Financial Condition and..
AQ
10/07PFIZER : Will Continue Helping Exact Sciences With Cologuard Promotion Through 2..
DJ
09/21EXACT SCIENCES CORP : Change in Directors or Principal Officers (form 8-K)
AQ
07/31EXACT SCIENCES : Management's Discussion and Analysis of Financial Condition and..
AQ
More news
Financials (USD)
Sales 2020 1 451 M - -
Net income 2020 -379 M - -
Net cash 2020 182 M - -
P/E ratio 2020 -48,4x
Yield 2020 -
Capitalization 18 796 M 18 796 M -
EV / Sales 2020 12,8x
EV / Sales 2021 10,2x
Nbr of Employees 4 110
Free-Float 99,1%
Chart EXACT SCIENCES CORPORATION
Duration : Period :
Exact Sciences Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EXACT SCIENCES CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 15
Average target price 150,43 $
Last Close Price 118,19 $
Spread / Highest target 36,2%
Spread / Average Target 27,3%
Spread / Lowest Target 18,5%
EPS Revisions
Managers
NameTitle
Kevin T. Conroy Chairman, President & Chief Executive Officer
Ana Hooker Senior Vice President-Operations
Jeffrey Thomas Elliott Chief Financial Officer
Graham Peter Lidgard Chief Science Officer, SVP-Research & Development
Sandra Statz SVP-Clinical & Regulatory Affairs
Sector and Competitors
1st jan.Capitalization (M$)
EXACT SCIENCES CORPORATION27.80%18 796
WUXI APPTEC CO., LTD.56.53%37 916
IQVIA HOLDINGS INC.9.26%32 365
BEIGENE, LTD.72.47%26 060
HANGZHOU TIGERMED CONSULTING CO.,LTD79.46%15 070
NEUROCRINE BIOSCIENCES, INC.-11.51%8 928